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Abstract
Background: Campylobacter spp. are among the most common bacterial causes of gastroenteritis world-wide and
mostly follow a benign course. We report two cases of Campylobacter jejuni-associated perimyocarditis, the first two
simultaneous cases published to date and the third and fourth cases over all in Sweden, and a review of the literature.
Case presentation: A previously healthy 24-yo male (A) presented at the Emergency Department(ED) with recent
onset of chest pain and a 3-day history of abdominal pain, fever and diarrhoea. The symptoms began within a few
hours of returning from a tourist visit to a central European capital. Vital signs were stable, the Electrocardiogram(ECG)
showed generalized ST-elevation, laboratory testing showed increased levels of C-reactive protein(CRP) and
high-sensitive Troponin T(hsTnT). Transthoracic echocardiogram (TTE) was normal, stool cultures were positive for C
Jejuni and blood cultures were negative. Two days after patient A was admitted to the ED his travel companion (B),
also a previously healthy male (23-yo), presented at the same ED with almost identical symptoms: chest pain
precipitated by a few days of abdominal pain, fever and diarrhoea. Patient B declared that he and patient A had
ingested chicken prior to returning from their tourist trip. Laboratory tests showed elevated CRP and hsTnT but the
ECG and TTE were normal. In both cases, the diagnosis of C jejuni-associated perimyocarditis was set based on the
typical presentation and positive stool cultures with identical strains. Both patients were given antibiotics, rapidly
improved and were fully recovered at 6-week follow up.
Conclusion: Perimyocarditis is a rare complication of C jejuni infections but should not be overlooked considering the
risk of heart failure. With treatment, the prognosis of full recovery is good but several questions remain to be answered
regarding the pathophysiology and the male preponderance of the condition.
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Background
Campylobacter spp. are among the most common bac-
terial causes of gastroenteritis world-wide and usually
the result of handling and consumption of poultry meat
[1]. Typical symptoms include diarrhoea, fever and ab-
dominal cramps. Infections are sometimes asymptom-
atic, often self-limiting and rarely require antibiotics.
Bacteraemia is seen in less than 1 % of cases, acute and
post-infectious complications are rare but include arth-
ritis, meningitis, endocarditis, sepsis and Guillain-Barré
syndrome [2, 3]. Myocarditis and perimyocarditis are
known but rare complications of C jejuni infections.
Here we present an unusual case where two previously
healthy males presented at the ED with diarrhoea and
chest pain and where the diagnosis of C jejuni-associated
perimyocarditis was set. We also present the results of a
review of the literature and discuss disease characteris-




A previously healthy 24-year-old male (A) presented at
the emergency department (ED) with chest pain and
diarrhoea. The chest pain began 2 h prior to hospital ad-
mission and was described as a constant light chest
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pressure without correlation to breathing or body pos-
ition. 3 days earlier, the patient and a friend had had
chicken in a restaurant before boarding a flight to
Sweden. One hour after arrival in Sweden the patient ex-
perienced sudden abdominal pain, chills and diarrhoea.
During the following three days the patient had 6 diar-
rhoeas per day, mucous but no visible blood. The patient
was diagnosed with C jejuni gastroenteritis after stool
culture at a primary care facility, no antibiotics were
given. Upon admission to the ED the abdominal pain
had subsided, the patient was afebrile (37 °C or 98.6 °F)
but still experiencing diarrhoea. Upon examination the
patient had normal circulatory and respiratory parameters.
Heart auscultation: regular rhythm (RR), no murmurs or
extra sounds. Lung and abdominal examinations were
normal. Laboratory examinations showed C-reactive pro-
tein (CRP) at 89.1 (normal range <10 mg/L), leukocyte
count (LC) at 11.3 (normal range 4-12 × 109/L) and high-
sensitive Troponin T (hsTnT) at 108 (normal range
<14 ng/L) ECG showed regular sinus rhythm, 64/min and
general 1 mm ST-elevation (Fig. 1). The patient was
treated with Brufen 200 mg (tid), Omeprazol 20 mg (qd)
and Loperamid 2 mg and admitted to a cardiac care unit
(CCU) for cardiac monitoring.
During the following 4 days the hsTnT reached a max-
imum value of 504 and then dropped to 46. Stool culture
confirmed the diagnosis of C jejuni. Blood cultures were
negative. Transthoracic echocardiogram (TTE) showed
normal right and left ventricle function, ejection fraction
(EF) 60–65 %, normal valvular structure and function, no
hypokinesia or pericardial effusion. After on day the ECG-
changes had resolved. The patient was started on ciproflox-
acin but developed urticarial rashes and severe itching and
the treatment was discontinued. The chest pain subsided
after 2 days and the patient left the hospital after 4 days.
The patient was given a 10 day prescription of Azithromy-
cin 500 mg (qd) upon hospital release. The diagnosis was
determined to be C jejuni-associated perimyocarditis
(CPM). At follow-up visit 4 weeks after discharge the pa-
tient was without complaints, physical examination was
normal and both ECG and TTE were normal.
Case 2
Two days after A was admitted to the ED with chest pain,
his travelling companion (B) presented on the same ED
with a 48-h history of mild constant chest pain exacer-
bated by breathing but not body position. B had, in the
same fashion as his companion A, developed abdominal
pain, diarrhoea and chills upon return to Sweden. After
initially experiencing multiple diarrhoeas daily, upon ad-
mission to the ED the diarrhoeas had started to subside
and the abdominal pain resolved. The patient was afebrile
(37.4 ° C or 99.3 °F), circulatory and respiratory parame-
ters as well as heart, lung and abdominal examination
were normal. Laboratory tests showed CRP at 46.5, LPK
at 9.1 and hsTnT at 128. The ECG was normal. The pa-
tient was admitted to a CCU for hsTnT-serial testing and
cardiac monitoring.
During the hospital stay the hsTnT reached a maximum
of 128 before dropping to 52. Stool cultures confirmed the
Fig. 1 Limb leads from 12-lead ECG from patient A showing typical generalized ST-segment elevation
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diagnosis of C jejuni sensitive to Azithromycin. Blood cul-
tures were negative. TTE showed normal right and left
ventricle function, normal valvular structure and function
and no pericardial effusion. The chest pain resolved within
48 h and the patient was released from the hospital with a
10-day prescription of Azithromycin 500 mg qd. The pa-
tient was given the diagnosis of C jejuni-associated peri-
myocarditis (CPM). At follow-up visit 4–6 weeks after
discharge the patient was doing well, physical examin-
ation, stress ECG and TTE were all normal.
Discussion
C jejuni infections are common but rarely lead to severe
symptoms outside of the gastrointestinal tract [2]. To date
only a few case reports [4, 5] have described C jejuni-
associated myocarditis/perimyocarditis (CPM) despite the
fact that C jejuni infections are one of the most common
causes of gastroenteritis word wide. In this case report we
present an unusual case of two previously healthy young
males who, after eating chicken at a restaurant, develop
typical gastroenteritis symptoms (abdominal pain, diar-
rhoea, chills) within 24 h and within 48–72 h of the onset
of gastroenteritis symptoms also develop chest pain. Based
on elevated hsTnT, typical ECG-findings (case A), positive
stool cultures, a lack of alternative plausible explana-
tions and a temporal association, the diagnosis of C
jejuni-associated perimyocarditis was set. Subsequent
analysis of both stool cultures demonstrated the pres-
ence of the same C jejuni strains with identical geno-
types. At follow up 4–6 weeks after discharge the
patient in case one was asymptomatic, the patient in
case 2 complained of unspecific fatigue that had resided
3 weeks later. Both patients had normal TTE and stress
ECG examinations.
This case report highlights several points of interest re-
garding pathogenesis and epidemiology of campylobacter-
associated perimyocarditis. Here follows a review of the
literature and further discussion of the case report.
A search on MEDLINE/PubMed using any combination
of the MESH-terms “Campylobacter”, “Campylobacter
jejuni” “myocarditis”, “perimyocarditis” and “pericarditis”
yielded 34 relevant articles 1979–2015. After cross check-
ing the reference lists two additional articles were found.
Including the characteristics of the two case reports pre-
sented above(Case A and B), a total of 44 cases; 20 cases
of myocarditis, 19 cases of perimyocarditis and five cases
of pericarditis associated with C jejuni infection have been
described in the literature. We review the baseline charac-
teristics of the patients based on the published case re-
ports (Table 1), and summarize the most recent case
reports in more detail (Table 2), review the clinical presen-
tation of C jejuni myocarditis, differential diagnosis and
diagnostic issues, treatment, pathophysiology and certain
disease characteristics.
The mean age was 29 years, 93 % of cases affected
men. Few patients had multiple comorbidities, a major-
ity of patients were previously healthy, but there were
also a substantial amount of cases that affected immuno-
compromised patients.
The clinical presentation is variable and there are no
pathognomonic symptoms or signs. Typically, the pa-
tient presents with a history of a few days of gastroenter-
itis (fever, abdominal pain, diarrhoea) and recent onset
of chest pain/discomfort/tightness. Vital signs are often
in the normal range. The ECG often shows signs of
tachycardia and generalized ST-elevation/depression/T-
wave inversion, easily mistaken for an acute coronary
syndrome resulting in normal coronary angiography
examinations. Additional differential diagnosis includes
valvular pathology and pulmonary embolism. Laboratory
investigations generally show elevated levels of cardiac
enzymes (Troponin T/I or Creatinine Kinases MB Isoen-
zyme (CKMB) as well as inflammation markers (CRP).
Additional diagnostic measures have traditionally in-
cluded TTE and, more recently, cardiac Magnetic Res-
onance Imaging (MRI). The TTE can sometimes reveal
decreased left ventricular ejection fraction (LVEF), wall
motion abnormalities and pericardial effusion. Cardiac
MRI is a non-invasive method that has gained popularity
lately. Subepicardial and myocardial enhancement can
be seen primarily in the left ventricle. Based on the com-
bination of symptoms (abdominal and chest symptoms)
and signs (ECG-changes and laboratory investigations)
the diagnosis of myocarditis is suspected and the patient
admitted to a cardiac care unit (CCU) for continuous
cardiac monitoring. The cardiac monitoring is often
uneventful but at least on case of severe arrhythmia
Table 1 Summary of baseline characteristics of all published
case reports including patient A and patient B. n = 44
[4–6, 10–12, 14, 18, 22–49]a,b
Characteristics
Age (years) Mean 29,4
Max 60
Min 15
Myocarditis n (%) All 20(100)
Female 0(0)
Male 20(100)
Perimyocarditis n (%) All 19(100)
Female 1(5)
Male 18(95)
Pericarditis n (%) All 4(100)
Female 3(75)
Male 1(25)
aCampylobacter not identified to the species level (ref [26] and [28])
bMean age (43 years old) of the patient series which included one case of
Campylobacter (ref [28])
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(ventricular tachycardia) has been described [6]. Historic-
ally, endomyocardial biopsy (EMB) has been performed
and is considered the gold standard for diagnosing myo-
carditis. However, there is a risk of complications related
to the procedure (although probably less common than
previously thought [7]. According to the AHA/ACCF/ESC
joint statement [8] and a recent review [9] EBM should be
performed in patients with severe symptoms (heart failure,
dilated cardiomyopathy, hemodynamic compromise) where
the risks are outweighed by the potential benefits. Pena
et al. [10] reported a rare case of C jejuni-associated myo-
carditis with pathological evidence of inflammation (but
no evidence of C jejuni on polymerase chain reaction
(PCR) study of the myocardium).
Treatment can be divided into supportive and causal.
Supportive treatment consists of preventing dehydration
and electrolyte disturbances and managing eventual heart
failure (Angiotensin receptor blocker/B adrenergic blocker)
or arrhythmias. Causal treatment consists of antibiotic
treatment; primarily Macrolides (Azithromycin/Roxithro-
mycin/Clarythromycin) and Flouroquinolones (Ciproflox-
acin) have been used. To the best of our knowledge there
is no consensus on dosage and treatment duration; when
reviewing recent cases the most common choice of anti-
biotic was the Macrolide Azithromycin, 500 mg qd for 3–
10 days [11] Full recovery and return to normal physical
status was noted in a vast majority of published cases.
Complications include persistent heart failure [12] and
ventricular arrhythmia [6]. Few cases with severe and fatal
outcome have been described in the literature, and all but
one had pre-existing conditions [10].
This case report highlights 3 points of interest.
1) We are, to our knowledge, the first to type a C
jejuni strain associated with myocarditis. Using
Pulse-field gel electrophoresis (PFGE) and the
restriction enzyme SMAL the two campylobacter
isolates showed identical patterns (Fig. 2) and the
same pattern of antibiotic resistance. No match of a
similar strain could be found in the Swedish
database of C jejuni strains, and the only similar
strain we could find was from a Swiss chicken isolate
from 2008 and this isolate was not associated with
any disease. The two cases in this report are also the
first ever described where the same C jejuni strain
caused myocarditis in two related cases. All previous
case reports have reported single cases of myocarditis.
This raises the question whether different
campylobacter strains have different affinity for the
myocardium. Our two cases represent the third and
fourth case of myocarditis ever described in Sweden,
which highlights the rare nature of the condition.
2) Our case report also highlight the need for further
investigation of the mechanisms of campylobacter-
associated myocarditis. Earlier studies have
speculated that there might be at least two types of
CPM: one bacteria/toxin mediated that causes acute
symptoms within 2–4 days of the gastroenteritis and
Table 2 Summary of the most recent case reports including case 1 (patient A)a and 2 (patient B)b. n = 14
Sex/Age Cardiac marker ECG Echo MRI Antibiotics Outcome
M/24a TnT 504 ng/L ST-elevation Normal, LVEF 60–65 % No Azithromycin Full recovery
M/23b TnT 128 ng/L Normal Normal incl LVEF No Azithromycin Full recovery
M/60 [6] N/A N/A Pericard effusion No Ceftriaxone/
Meropenem
Diarroea





M/33 [8] TnI 18.6mcg/L ST-elevation LVEF 56 % Increased signal subepi,
dilated LV/RV
Roxithromycin N/A
M/17 [9] TnI 16.8 ng/mL ST-elevation Normal Subepicardial enhancement Azithromycin Full recovery
M/21 [5] TnI 15.6 ng/ml Normal Decreased LVEF Subepi/myocardial
enhancement
Azithromycin Almost full rec
M/24 [5] TnI 8.9 mcg/L ST-elevation LVEF 40 % Subepicardial enhancement No Full recovery
M/42 [5] TnI 11.6mcg/L ST-elevation LVEF 40 % Subepicardial enhancement Ciprofloxacin Full recovery
M/21 [10] TnI 39.8mcg/L ST-elevation Normal inkc LVEF No Ciprofloxacin Full recovery
M/21 [11] TnI 2.5mcg/L ST-elevation Normal incl LVEF No Yes(unknown kind) Full recovery
M/24 [12] CK normal Arrythmia Decreased LVEF/
peric effusion
No Roxithromycin N/A
M/19 [13] TnT 0.52 ng/mL Strain N/A Yes N/A N/A
M/16 [14] TnT 1.7 ng/mL ST-elevation LVEF 45 % No Clarythromycin Full recovery
M/17 [14] TnT 0.9 ng/mL ST-elevation Normal incl LVEF Myocardial enhancement Clarythromycin Full recovery
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another, immunological type, that causes delayed
symptoms 2 weeks after the onset of the infection
[13]. Neither type has been particularly well
characterized, there is to our knowledge only one
case of C jejuni-myocarditis with pathological
confirmation [10]. Alzand et al. speculate that
several mechanisms, apart from direct bacterial
invasion, such as bacterial toxins, circulating
immune complexes or cytotoxic T-cells might be
involved [14]. In 2007 Becker et at studied a Danish
cohort of 6204 cases of C jejuni-gastroenteritis and
found no increase in myocarditis incidence in the C
jejuni cohort and no cases of pericarditis as
compared to age matched controls. Because of the
patient selection, retrospective study design and the
very low incidence of myocarditis (1/6204) and
pericarditis (0/6204) in the C jejuni-cohort the
authors limited their conclusion to state that they
did not observe an increased incidence of myocarditis
or pericarditis. The authors offered an intriguing but
speculative hypothesis for the aetiology of
campylobacter-associated myocarditis: the possibility
of a viral co-infection that might be the actual cause
of the perimyocarditis/myocarditis.
Because of the relatively acute onset of chest pain in
relation to the debut of the infection, one might
speculate that the most probable cause of
myocarditis in this case report is a bacteria/toxin
effect. The fact that blood cultures were negative
does not rule out transient bacteraemia or a toxin
effect. Less than 1 out of 100 Campylobacter
gastroenteritis infections have positive blood
cultures [15] which have led some to believe that we
under-diagnose Campylobacterimia [16]. A recent
study by Harvala et al. showed an increase in the
number of Campylobacteremia cases in Sweden in
2014 as a result of improvements in blood culture
medium [17] This fact could explain why, in the
presently described as well as in all previously
described cases of myocarditis/perimyocarditis/
pericarditis apart from one case of pericarditis [18],
blood cultures have been negative. This patient was
also immunocompromised due to an X-linked
Agammaglobulinemia, and one can speculate that
this could affect the disease mechanism.
3) This case report and literature review also highlights
the fact that (young) men seem to be affected by
campylobacter-associated myocarditis/perimyocarditis
to a larger extent than women. The incidence of C
jejuni gastroenteritis is slightly higher for men than
women but almost all reported CPM have affected
men [2]. This observation has been made several
times before, but no explanation has been offered. If
one combines all reported cases of myocarditis and
perimyocarditis associated with C jejuni infection
described in the literature to date, only 7 % affect
women (4/43). A comparison with the incidence of
other bacteria-associated types of myocarditis is
difficult because of lack of reliable studies. It is a well-
known fact that most types of cardiovascular disease
have a higher incidence and prevalence among men
than women (at least up to the age of 75) [19], and
recent reports [20] have shown and confirmed a
higher incidence of myocarditis in men as compared
to women. The exact mechanisms for this is not
known but some authors speculate that factors such
as sex hormones (both testosterone as well as the
female sex hormones), the immune system and
genomics as well as differences in clinical manifestation
and treatment might play a role [21].
Conclusion
Myocarditis and perimyocarditis are rare complications of
C jejuni infections that predominantly affect young previ-
ously healthy men and in the majority of cases follow a be-
nign course. More studies are needed to elucidate the
characteristics and pathogenesis of this rare condition.
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